Literature DB >> 10411608

Comparison of the ligand binding and signaling properties of human dopamine D(2) and D(3) receptors in Chinese hamster ovary cells.

J F Vanhauwe1, N Fraeyman, B J Francken, W H Luyten, J E Leysen.   

Abstract

Human dopamine D(2) (hD(2)) and D(3) (hD(3)) receptors were expressed at similar, high expression levels in Chinese hamster ovary (CHO) cells, and their coupling to G proteins and further signal transduction pathways were compared. In competition radioligand-binding experiments, guanosine-5'-O-(3-thio)triphosphate (GTPgammaS) treatment of hD(2S)- or hD(3)-CHO cell membranes induced a rightward shift and steeping of the dopamine inhibition curve. This effect was pronounced for hD(2) receptors and small for hD(3) receptors. Activation of G proteins was investigated in [(35)S]GTPgammaS-binding assays. Dopamine stimulated [(35)S]GTPgammaS binding 330 and 70% over basal levels on hD(2)-CHO and hD(3)-CHO cell membranes, respectively. (+)-7-(Dipropylamino)-5, 6,7,8-tetrahydro-2-naphthalenol and PD128907 were partial agonists for both receptors. Haloperidol, risperidone, raclopride, and nemonapride inhibited dopamine-stimulated [(35)S]GTPgammaS binding with potencies comparable to their binding affinities for hD(2) and hD(3) receptors in CHO cell membranes; inverse agonism could not be detected with this assay. Receptor stimulation by dopamine inhibited forskolin-induced cyclic AMP formation in hD(2)-CHO and hD(3)-CHO cells by 70%. Furthermore, the extracellular acidification rate increased when hD(2)-CHO and hD(3)-CHO cells were stimulated by dopamine; this effect was abolished by pertussis toxin pretreatment. In this study, we could demonstrate clear functional effects at different levels of the signaling cascade of hD(2) and hD(3) receptors in CHO cells when expressed at high levels. High-affinity agonist binding to hD(2) and hD(3) receptors was still present, but effects of receptor-G protein uncoupling at hD(3) receptors were small, indicating that hD(3) receptors maintain relatively high-affinity agonist binding in the absence of G proteins.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411608

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  Most central nervous system D2 dopamine receptors are coupled to their effectors by Go.

Authors:  M Jiang; K Spicher; G Boulay; Y Wang; L Birnbaumer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

2.  Efficacy of Hybrid Tetrahydrobenzo[d]thiazole Based Aryl Piperazines D-264 and D-301 at D₂ and D₃ Receptors.

Authors:  Maarten E A Reith; Aloke K Dutta; Dana E Selley; Juan Zhen; Tamara Antonio; Joanna C Jacob; David K Grandy
Journal:  Neurochem Res       Date:  2015-12-31       Impact factor: 3.996

3.  Pharmacological characterization of 2-methoxy-N-propylnorapomorphine's interactions with D2 and D3 dopamine receptors.

Authors:  Mette Skinbjerg; Yoon Namkung; Christer Halldin; Robert B Innis; David R Sibley
Journal:  Synapse       Date:  2009-06       Impact factor: 2.562

4.  The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts.

Authors:  Pierre Savi; Jean-Luc Zachayus; Nathalie Delesque-Touchard; Catherine Labouret; Caroline Hervé; Marie-Françoise Uzabiaga; Jean-Marie Pereillo; Jean-Michel Culouscou; Françoise Bono; Pascual Ferrara; Jean-Marc Herbert
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-11       Impact factor: 11.205

Review 5.  Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism.

Authors:  Georges Vauquelin; Sophie Bostoen; Patrick Vanderheyden; Philip Seeman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-14       Impact factor: 3.000

6.  YQA14: a novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice.

Authors:  Rui Song; Ri-Fang Yang; Ning Wu; Rui-Bin Su; Jin Li; Xiao-Qing Peng; Xia Li; József Gaál; Zheng-Xiong Xi; Eliot L Gardner
Journal:  Addict Biol       Date:  2011-04-20       Impact factor: 4.280

7.  Dopamine D3 and D2 receptor mechanisms in the abuse-related behavioral effects of cocaine: studies with preferential antagonists in squirrel monkeys.

Authors:  Cindy Achat-Mendes; Peter Grundt; Jianjing Cao; Donna M Platt; Amy Hauck Newman; Roger D Spealman
Journal:  J Pharmacol Exp Ther       Date:  2010-05-21       Impact factor: 4.030

8.  Inhibitory Effectiveness in Delayed-Rectifier Potassium Current Caused by Vortioxetine, Known to Be a Novel Antidepressant.

Authors:  Hung-Tsung Hsiao; Jeffrey Chi-Fei Wang; Sheng-Nan Wu
Journal:  Biomedicines       Date:  2022-06-03

9.  The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease.

Authors:  Dieter Scheller; Christoph Ullmer; Reinhard Berkels; Mirella Gwarek; Hermann Lübbert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-08-14       Impact factor: 3.000

10.  Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity.

Authors:  Mu-Fa Zou; Thomas M Keck; Vivek Kumar; Prashant Donthamsetti; Mayako Michino; Caitlin Burzynski; Catherine Schweppe; Alessandro Bonifazi; R Benjamin Free; David R Sibley; Aaron Janowsky; Lei Shi; Jonathan A Javitch; Amy Hauck Newman
Journal:  J Med Chem       Date:  2016-04-01       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.